PIA
SRPT icon

Piedmont Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Piedmont Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,204
Closed -$607K – 602
2020
Q1 		$607K Buy
6,204
+930
+18% +$106K 0.02% 403
2019
Q4 		$681K Buy
5,274
+30
+0.6% +$3.03K 0.02% 430
2019
Q3 		$395K Buy
5,244
+61
+1% +$7.2K 0.02% 622
2019
Q2 		$788K Buy
5,183
+344
+7% +$41.8K 0.03% 386
2019
Q1 		$577K Buy
4,839
+18
+0.4% +$2.31K 0.02% 462
2018
Q4 		$526K Buy
4,821
+280
+6% +$35K 0.03% 445
2018
Q3 		$733K Buy
+4,541
New +$621K 0.03% 378

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Piedmont Investment Advisors's SRPT Position: Q2 2020 in Review

Piedmont Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2020, closing a stake of 6,204 shares — an estimated $607K sold.

Piedmont Investment Advisors first reported a position in SRPT in Q3 2018 and held it in 7 quarters. The position peaked at $788K in Q2 2019. 409 funds tracked by Wall St. Rank hold SRPT as of Q2 2020.

  • Piedmont Investment Advisors reported no remaining Sarepta Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Piedmont Investment Advisors sold 6,204 Sarepta Therapeutics shares in Q2 2020, an estimated $607K.
  • Piedmont Investment Advisors first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 7 quarters.
  • Piedmont Investment Advisors's Sarepta Therapeutics position peaked at $788K in Q2 2019.
  • 409 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2020.

Based on Piedmont Investment Advisors's 13F filing for Q2 2020.